Fig. 3 | British Journal of Cancer

Fig. 3

From: A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

Fig. 3

Kaplan–Meier curves for time to disease progression in a, all dosed patients, and b, expanded safety cohort. The number and percentage of patients with disease progression and the median number of days (and 95% CIs) to disease progression are detailed per cancer type. Censored events are depicted within each graph, and the numbers of patients at risk per cancer type are listed for each depicted timepoint. CI confidence interval, NR not reached

Back to article page